Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, ' Diffuse Large B-Cell Lymphoma Pipeline Insight ' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell Lymphoma pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Diffuse Large B-Cell Lymphoma Pipeline Report to explore emerging therapies, key Diffuse Large B-Cell Lymphoma Companies, and future Diffuse Large B-Cell Lymphoma treatment landscapes @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
In February 2025:- Genmab:- This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed.
In February 2025:- Pfizer:- This study is seeking participants who are unable or unwilling to undergo an autologous stem cell transplantation (when doctors put healthy blood cells back into your body) or CAR-T immune cell therapy. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections.
In February 2025:- Hoffmann-La Roche- The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.
In February 2025:- Incyte Corporation:- This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.
DelveInsight's Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Promising Diffuse Large B-Cell Lymphoma Therapies such as Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Discover how the Diffuse Large B-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth Diffuse Large B-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ Diffuse Large B-Cell Lymphoma Clinical Trials and Studies
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok's proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
The Diffuse Large B-Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-Cell Lymphoma Treatment.
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diffuse Large B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-Cell Lymphoma market.
Get a detailed analysis of the latest innovations in the Diffuse Large B-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-Cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Diffuse Large B-Cell Lymphoma Therapies and key Diffuse Large B-Cell Lymphoma Developments @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
Coverage- Global
Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutic, Otsuka Pharmaceutical, OncoNano Medicine, Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology and others.
Diffuse Large B-Cell Lymphoma Therapies - Ibrutinib, Bendamustine, Rituximab, R-miniCHOP, Selinexor, Tafasitamab, Lenalidomide, and others.
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Diffuse Large B-Cell Lymphoma drug development? Find out in DelveInsight's exclusive Diffuse Large B-Cell Lymphoma Pipeline Report—access it now! @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Diffuse Large B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Large B-Cell Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Brentuximab vedotin: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
THOR-707: Sanofi
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADI-001: Adicet Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Large B-Cell Lymphoma Key Companies
Diffuse Large B-Cell Lymphoma Key Products
Diffuse Large B-Cell Lymphoma- Unmet Needs
Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
Diffuse Large B-Cell Lymphoma Analyst Views
Diffuse Large B-Cell Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ottawa Citizen
17 hours ago
- Ottawa Citizen
Noah Dobson will be highest-paid Canadiens player on ice next season
Canadiens general manager Kent Hughes wouldn't have acquired Noah Dobson from the New York Islanders if the 25-year-old defenceman wouldn't agree to a long-term contract. Article content That's why Hughes asked Islanders GM Mathieu Darche for permission to speak with Dobson's agent before finalizing the trade on Friday that brought the defenceman to the Canadiens in exchange for the 16th and 17th overall picks at the NHL Draft, along with 23-year-old forward Emil Heineman. Article content Article content The Islanders were the only team that could offer Dobson a maximum-length contract, so it was technically Darche who signed the Summerside, P.E.I., native to the eight-year, US$76-million contract with an annual salary-cap hit of US$9.5 million in the sign-and-trade deal. But it was Hughes who negotiated it. Article content Article content Article content The contract makes Dobson the highest-paid player on the Canadiens — not counting the US$10.5 million for Carey Price in the final year of his contract while the goalie remains on long-term injured reserve before officially retiring. Patrik Laine now ranks second with a salary-cap hit of US$8.7 million, followed by captain Nick Suzuki at US$7.875 million, Cole Caufield at US$7.85 million and Juraj Slafkovsky at US$7.6 million. When Jeff Gorton, the executive vice-president of hockey operations, and Hughes started rebuilding the Canadiens three years ago, Suzuki's contract — signed with former GM Marc Bergevin — was considered the ceiling, which is why Caufield earns US$25,000 less than the captain. But times have changed as the Canadiens' rebuilding plan moves forward and the NHL salary cap jumps from US$88 million last season to US$95.5 million next season, US$104 million for 2026-27 and US$113.5 million for 2027-28. Article content Article content Hughes noted the contracts he negotiated for Caufield and Slafkovsky were for players coming off three-year, NHL entry-level deals and the parameters were completely different for a player like Dobson, with six years of NHL experience. It will be interesting to see what the parameters will be for Lane Hutson's next contract after he won the Calder Trophy this season as the NHL's top rookie. Hutson entry-level deal that has a US$950,000 salary-cap hit has one season left and the 21-year-old can become a restricted free agent next summer. Article content It wouldn't be a surprise if Hutson becomes the Canadiens' highest-paid player with the new salary-cap structure. Then, Hughes will have to think about a new contract for Ivan Demidov, who can become a restricted free agent in two years. What will help Hughes two years from now is the contracts for veterans Brendan Gallagher (US$6.5 million cap hit) and Josh Anderson (US$5.5 million) will come to an end.
Edmonton Journal
18 hours ago
- Edmonton Journal
Noah Dobson will be highest-paid Canadiens player on ice next season
Article content Canadiens general manager Kent Hughes wouldn't have acquired Noah Dobson from the New York Islanders if the 25-year-old defenceman wouldn't agree to a long-term contract. That's why Hughes asked Islanders GM Mathieu Darche for permission to speak with Dobson's agent before finalizing the trade on Friday that brought the defenceman to the Canadiens in exchange for the 16th and 17th overall picks at the NHL Draft, along with 23-year-old forward Emil Heineman. Article content Article content The Islanders were the only team that could offer Dobson a maximum-length contract, so it was technically Darche who signed the Summerside, P.E.I., native to the eight-year, US$76-million contract with an annual salary-cap hit of US$9.5 million in the sign-and-trade deal. But it was Hughes who negotiated it. The contract makes Dobson the highest-paid player on the Canadiens — not counting the US$10.5 million for Carey Price in the final year of his contract while the goalie remains on long-term injured reserve before officially retiring. Patrik Laine now ranks second with a salary-cap hit of US$8.7 million, followed by captain Nick Suzuki at US$7.875 million, Cole Caufield at US$7.85 million and Juraj Slafkovsky at US$7.6 million. When Jeff Gorton, the executive vice-president of hockey operations, and Hughes started rebuilding the Canadiens three years ago, Suzuki's contract — signed with former GM Marc Bergevin — was considered the ceiling, which is why Caufield earns US$25,000 less than the captain. But times have changed as the Canadiens' rebuilding plan moves forward and the NHL salary cap jumps from US$88 million last season to US$95.5 million next season, US$104 million for 2026-27 and US$113.5 million for 2027-28. Article content Hughes noted the contracts he negotiated for Caufield and Slafkovsky were for players coming off three-year, NHL entry-level deals and the parameters were completely different for a player like Dobson, with six years of NHL experience. It will be interesting to see what the parameters will be for Lane Hutson's next contract after he won the Calder Trophy this season as the NHL's top rookie. Hutson entry-level deal that has a US$950,000 salary-cap hit has one season left and the 21-year-old can become a restricted free agent next summer. It wouldn't be a surprise if Hutson becomes the Canadiens' highest-paid player with the new salary-cap structure. Then, Hughes will have to think about a new contract for Ivan Demidov, who can become a restricted free agent in two years. What will help Hughes two years from now is the contracts for veterans Brendan Gallagher (US$6.5 million cap hit) and Josh Anderson (US$5.5 million) will come to an end. Article content Dobson's agent, Olivier Fortier, told Kevin Dubé of the Journal de Montréal the defenceman was offered more money by other teams before joining the Canadiens. 'As a general manager, I think that's very important,' Hughes, a former player agent, said with a chuckle. 'Some people may call me a hypocrite. I think it's very important. 'Listen, I represented hockey players,' Hughes added. 'A lot of them who made that decision. I always felt as an agent — and, obviously, Noah's agent feels the same way — that players drive decisions and they own their careers and we're here to kind of help guide them through. 'In my experience representing hockey players, once they get a taste of winning they chase it,' Hughes continued. 'They chase it and some of them look back and say: 'I wish I had figured it out sooner and chased it sooner.' I don't think there's a lot of players in Florida that are regretting that they took less money to stay in Florida (with the Panthers winning back-to-back Stanley Cups). That's a credit to the Florida Panthers organization for creating an environment where they can win and where they enjoy being there and working together, and that's what we're trying to do here.' Latest National Stories
Vancouver Sun
18 hours ago
- Vancouver Sun
Noah Dobson will be highest-paid Canadiens player on ice next season
Canadiens general manager Kent Hughes wouldn't have acquired Noah Dobson from the New York Islanders if the 25-year-old defenceman wouldn't agree to a long-term contract. That's why Hughes asked Islanders GM Mathieu Darche for permission to speak with Dobson's agent before finalizing the trade on Friday that brought the defenceman to the Canadiens in exchange for the 16th and 17th overall picks at the NHL Draft, along with 23-year-old forward Emil Heineman . The Islanders were the only team that could offer Dobson a maximum-length contract, so it was technically Darche who signed the Summerside, P.E.I., native to the eight-year, US$76-million contract with an annual salary-cap hit of US$9.5 million in the sign-and-trade deal. But it was Hughes who negotiated it. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The contract makes Dobson the highest-paid player on the Canadiens — not counting the US$10.5 million for Carey Price in the final year of his contract while the goalie remains on long-term injured reserve before officially retiring. Patrik Laine now ranks second with a salary-cap hit of US$8.7 million, followed by captain Nick Suzuki at US$7.875 million, Cole Caufield at US$7.85 million and Juraj Slafkovsky at US$7.6 million. When Jeff Gorton, the executive vice-president of hockey operations, and Hughes started rebuilding the Canadiens three years ago, Suzuki's contract — signed with former GM Marc Bergevin — was considered the ceiling, which is why Caufield earns US$25,000 less than the captain. But times have changed as the Canadiens' rebuilding plan moves forward and the NHL salary cap jumps from US$88 million last season to US$95.5 million next season, US$104 million for 2026-27 and US$113.5 million for 2027-28. Hughes noted the contracts he negotiated for Caufield and Slafkovsky were for players coming off three-year, NHL entry-level deals and the parameters were completely different for a player like Dobson, with six years of NHL experience. It will be interesting to see what the parameters will be for Lane Hutson's next contract after he won the Calder Trophy this season as the NHL's top rookie. Hutson entry-level deal that has a US$950,000 salary-cap hit has one season left and the 21-year-old can become a restricted free agent next summer. It wouldn't be a surprise if Hutson becomes the Canadiens' highest-paid player with the new salary-cap structure. Then, Hughes will have to think about a new contract for Ivan Demidov, who can become a restricted free agent in two years. What will help Hughes two years from now is the contracts for veterans Brendan Gallagher (US$6.5 million cap hit) and Josh Anderson (US$5.5 million) will come to an end. Dobson's agent, Olivier Fortier, told Kevin Dubé of the Journal de Montréal the defenceman was offered more money by other teams before joining the Canadiens. 'As a general manager, I think that's very important,' Hughes, a former player agent, said with a chuckle. 'Some people may call me a hypocrite. I think it's very important. 'Listen, I represented hockey players,' Hughes added. 'A lot of them who made that decision. I always felt as an agent — and, obviously, Noah's agent feels the same way — that players drive decisions and they own their careers and we're here to kind of help guide them through. 'In my experience representing hockey players, once they get a taste of winning they chase it,' Hughes continued. 'They chase it and some of them look back and say: 'I wish I had figured it out sooner and chased it sooner.' I don't think there's a lot of players in Florida that are regretting that they took less money to stay in Florida (with the Panthers winning back-to-back Stanley Cups). That's a credit to the Florida Panthers organization for creating an environment where they can win and where they enjoy being there and working together, and that's what we're trying to do here.'
